M1 Macrophage Exosomes MiR-21a-5p Aggravates Inflammatory Bowel Disease Through Decreasing E-cadherin and Subsequent ILC2 Activation

Overview

Journal J Cell Mol Med

Specialties Cell Biology
Molecular Biology

Date 2021 Feb 11

PMID 33569850

Citations 20

Authors

Jiaxi Lu

Deliang Liu

Yuyong Tan

Feihong Deng

Rong Li

Affiliations

Soon will be listed here.

Abstract

Abnormal immune regulation is a key feature of the complex pathogenic mechanism of ulcerative colitis (UC). In particular, macrophages and group 2 innate lymphoid cells (ILC2s) are important components of natural immunity that have been shown to play important roles in the pathogenesis of UC, as well as decreased E-cadherin expression on the colonic mucosa. However, it remains unclear how these components interact with each other. In this study, we investigated the molecular mechanisms of UC mediated by macrophage-derived exosomes. We showed for the first time that miR-21a-5p expression is increased in the peritoneal exosomes of mice with dextran sulphate sodium induced enteritis and that miR-21a-5p expression correlates negatively with E-cadherin expression in enterocytes. Moreover, we confirmed that miR-21a-5p was mainly derived from M1 macrophages and demonstrated that KLRG1, a surface inhibitory receptor on ILC2s, participated in excessive ILC2 activation in UC by promoting GATA-3. In conclusion, our results suggest molecular targets and provide a theoretical basis for elucidating the pathogenesis of UC and improving its treatment.

Citing Articles

Role of E-cadherin in epithelial barrier dysfunction: implications for bacterial infection, inflammation, and disease pathogenesis.

Lialios P, Alimperti S Front Cell Infect Microbiol. 2025; 15:1506636.

PMID: 40007608 PMC: 11850337. DOI: 10.3389/fcimb.2025.1506636.

Macrophage-derived extracellular vesicles as new players in chronic non-communicable diseases.

Lin F, Luo H, Wang J, Li Q, Zha L Front Immunol. 2025; 15:1479330.

PMID: 39896803 PMC: 11782043. DOI: 10.3389/fimmu.2024.1479330.

-Derived Exosome-Like Nanoparticles Mitigate Colitis in Mice via Inhibition of the NLRP3 Signaling Pathway and Modulation of the Gut Microbiota.

Li J, Xu J, Huang C, Hu J, Xu H, Guo X Int J Nanomedicine. 2025; 19:13991-14018.

PMID: 39742094 PMC: 11687308. DOI: 10.2147/IJN.S493434.

Circulating plasma derived exosomes from systemic lupus erythematosus aggravate lupus nephritis through miR-122-5p/FOXO3-mediated macrophage activation.

Ji J, He Q, Xia Y, Sha X, Liang Q, Xu Y J Nanobiotechnology. 2024; 22(1):779.

PMID: 39702207 PMC: 11657265. DOI: 10.1186/s12951-024-03063-6.

Cell-derived biomimetic drug delivery system for inflammatory bowel disease therapy.

Yang W, Lin P, Gao R, Fang Z, Wang Z, Ma Z Mater Today Bio. 2024; 29:101332.

PMID: 39606424 PMC: 11600033. DOI: 10.1016/j.mtbio.2024.101332.

References

Neill D, Wong S, Bellosi A, Flynn R, Daly M, Langford T . Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature. 2010; 464(7293):1367-70. PMC: 2862165. DOI: 10.1038/nature08900. View

Melis L, Van Praet L, Pircher H, Venken K, Elewaut D . Senescence marker killer cell lectin-like receptor G1 (KLRG1) contributes to TNF-α production by interaction with its soluble E-cadherin ligand in chronically inflamed joints. Ann Rheum Dis. 2013; 73(6):1223-31. DOI: 10.1136/annrheumdis-2013-203881. View

Ungaro R, Mehandru S, Allen P, Peyrin-Biroulet L, Colombel J . Ulcerative colitis. Lancet. 2016; 389(10080):1756-1770. PMC: 6487890. DOI: 10.1016/S0140-6736(16)32126-2. View

Nagasawa M, Heesters B, Kradolfer C, Krabbendam L, Martinez-Gonzalez I, de Bruijn M . KLRG1 and NKp46 discriminate subpopulations of human CD117CRTH2 ILCs biased toward ILC2 or ILC3. J Exp Med. 2019; 216(8):1762-1776. PMC: 6683990. DOI: 10.1084/jem.20190490. View

Tindemans I, Serafini N, Di Santo J, Hendriks R . GATA-3 function in innate and adaptive immunity. Immunity. 2014; 41(2):191-206. DOI: 10.1016/j.immuni.2014.06.006. View

Zhu Y, Li X, Chen J, Chen T, Shi Z, Lei M . The pentacyclic triterpene Lupeol switches M1 macrophages to M2 and ameliorates experimental inflammatory bowel disease. Int Immunopharmacol. 2015; 30:74-84. DOI: 10.1016/j.intimp.2015.11.031. View

Kadel S, Ainsua-Enrich E, Hatipoglu I, Turner S, Singh S, Khan S . A Major Population of Functional KLRG1 ILC2s in Female Lungs Contributes to a Sex Bias in ILC2 Numbers. Immunohorizons. 2018; 2(2):74-86. PMC: 5860819. DOI: 10.4049/immunohorizons.1800008. View

Yang F, Wang D, Li Y, Sang L, Zhu J, Wang J . Th1/Th2 Balance and Th17/Treg-Mediated Immunity in relation to Murine Resistance to Dextran Sulfate-Induced Colitis. J Immunol Res. 2017; 2017:7047201. PMC: 5444015. DOI: 10.1155/2017/7047201. View

Lu J, Liu D, Tan Y, Deng F, Li R . M1 Macrophage exosomes MiR-21a-5p aggravates inflammatory bowel disease through decreasing E-cadherin and subsequent ILC2 activation. J Cell Mol Med. 2021; 25(6):3041-3050. PMC: 7957199. DOI: 10.1111/jcmm.16348. View

10.

Keane T, Dziki J, Sobieski E, Smoulder A, Castleton A, Turner N . Restoring Mucosal Barrier Function and Modifying Macrophage Phenotype with an Extracellular Matrix Hydrogel: Potential Therapy for Ulcerative Colitis. J Crohns Colitis. 2016; 11(3):360-368. DOI: 10.1093/ecco-jcc/jjw149. View

11.

Salimi M, Barlow J, Saunders S, Xue L, Gutowska-Owsiak D, Wang X . A role for IL-25 and IL-33-driven type-2 innate lymphoid cells in atopic dermatitis. J Exp Med. 2013; 210(13):2939-50. PMC: 3865470. DOI: 10.1084/jem.20130351. View

12.

Yunna C, Mengru H, Lei W, Weidong C . Macrophage M1/M2 polarization. Eur J Pharmacol. 2020; 877:173090. DOI: 10.1016/j.ejphar.2020.173090. View

13.

Sarode P, Schaefer M, Grimminger F, Seeger W, Savai R . Macrophage and Tumor Cell Cross-Talk Is Fundamental for Lung Tumor Progression: We Need to Talk. Front Oncol. 2020; 10:324. PMC: 7078651. DOI: 10.3389/fonc.2020.00324. View

14.

Kabata H, Moro K, Koyasu S . The group 2 innate lymphoid cell (ILC2) regulatory network and its underlying mechanisms. Immunol Rev. 2018; 286(1):37-52. DOI: 10.1111/imr.12706. View

15.

Nemeth Z, Bogdanovski D, Barratt-Stopper P, Paglinco S, Antonioli L, Rolandelli R . Crohn's Disease and Ulcerative Colitis Show Unique Cytokine Profiles. Cureus. 2017; 9(4):e1177. PMC: 5438231. DOI: 10.7759/cureus.1177. View

16.

Hoving J . Targeting IL-13 as a Host-Directed Therapy Against Ulcerative Colitis. Front Cell Infect Microbiol. 2018; 8:395. PMC: 6232290. DOI: 10.3389/fcimb.2018.00395. View

17.

Mavroudis G, Magnusson M, Isaksson S, Sundin J, Simren M, Ohman L . Mucosal and Systemic Immune Profiles Differ During Early and Late Phases of the Disease in Patients With Active Ulcerative Colitis. J Crohns Colitis. 2019; 13(11):1450-1458. DOI: 10.1093/ecco-jcc/jjz072. View

18.

van Niel G, DAngelo G, Raposo G . Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol. 2018; 19(4):213-228. DOI: 10.1038/nrm.2017.125. View

19.

Zhang J, Zhao Y, Hou T, Zeng H, Kalambhe D, Wang B . Macrophage-based nanotherapeutic strategies in ulcerative colitis. J Control Release. 2020; 320:363-380. DOI: 10.1016/j.jconrel.2020.01.047. View

20.

Yang C, Zhang M, Sung J, Wang L, Jung Y, Merlin D . Autologous Exosome Transfer: A New Personalised Treatment Concept to Prevent Colitis in a Murine Model. J Crohns Colitis. 2019; 14(6):841-855. PMC: 7346889. DOI: 10.1093/ecco-jcc/jjz184. View